Moreover, adropin levels < 2.30 ng/mL independently predicted CKD 1–3 grades in T2DM patients with chronic HF, which may be considered a novel biomarker-based approach for stratifying HF patients at CKD risk during management. The gene discussed is ENHO; the disease is type 2 diabetes mellitus.